top 10 selling pharma product

1. Best Selling
Pharma Products
Prepared By:
Mrinal Patil (P-011)
Alay Joshi (P-008)
Rohit Patel (Q-003)

2. GLOBAL PHARMA MARKET SCENARIO
• Global Pharmaceutical Market Report & Forecast: 2012-2017” :
The global pharmaceutical market is expected to grow at a CAGR
of 5% during 2011-2017 exceeding sales worth US$ 1.1 Trillion by
2017.
• The research identifies that sales of generic drugs will emerge as
the most prominent segment of the pharma market during the
forecast period, indicating large opportunities for generics
manufacturers .
• Spending on medicines which was estimated at $856 billion in
2010, is expected to reach nearly $1,100 billion in 2015, reflecting a
slowing growth rate of 36 % over the five year period compared to
6.2 per cent annual growth over the past five years2

4. Top 10 Global
Pharma Products
Products Rank Growth Rate
(%)
Humira 1 22.1
Lantus 2 30.4
Sovaldi 3 98.64
Abilify 4 19.2
Enbrel 5 11.0
Seretide 6 -5.3
Crestor 7 5.6
Remicade 8 7.7
Nexium 9 -1.4
Mabthera 10 4.3

5. HUMIRA
• Humira is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic
arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa.
• It is also used to treatCrohn's disease or ulcerative colitis

6. Lantus
8014
10331
0
2000
4000
6000
8000
10000
12000
2013 2014
Sales (US $million)

7. SOVALDI
• Sovaldi is an antiviral medication that prevents hepatitis C virus
(HCV) cells from multiplying in the body.
70
9375
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
2013 2014
Sales (US $million)

8. Abilify
• Abilify is used to treat the symptoms of psychotic conditions such as
schizophrenia and bipolar disorder (manic depression). It is also used together
with other medications to treat major depressive disorder in adults

9. ENBREL
Enbrel is used to treat the symptoms of rheumatoid
arthritis, psoriatic arthritis, or ankylosing spondylitis, and
to prevent joint damage caused by these conditions

10. Seretide
7705
8907
9,198
8,652
6500
7000
7500
8000
8500
9000
9500
2011 2012 2013 2014
Revenues in US million Dollars
It is used to treatment of asthma and chronic
obstructive pulmonary disease (COPD).

11. CRESTOR
8136
8215
8,140
8,473
7900
8000
8100
8200
8300
8400
8500
2011 2012 2013 2014
Revenues in US million Dollars
It is used to treat high cholesterol and related
conditions, and to prevent cardiovascular disease.
Crestor is the fourth-highest selling drug in the
United States, accounting for approx. $5.2 billion
in sales in 2013.

12. REMICADE
7259
7678
7000
7100
7200
7300
7400
7500
7600
7700
7800
2012 2013
Remicade Sales
Sales ( US $ million)
Remicade is used to treat rheumatoid
arthritis. It is also used to treat Crohn's
disease or ulcerative colitis.
Patent holder- Johnson & Johnson
• In the United States, remicade can cost
$19,000 to $22,000 a year per patient.
• Johnson & Johnson reported in its 2013
annual report, "REMICADE® (infliximab),
accounted for approximately 9.4% of the
Company's total revenues for fiscal 2013.

13. Nexium
Nexium (esomeprazole) is a proton pump inhibitor that
decreases the amount of acid produced in the stomach.
Nexium is used to treat symptoms of gastroesophageal reflux
disease (GERD) and other conditions involving excessive
stomach acid such as Zollinger-Ellison syndrome. It is also used to
promote healing of erosive esophagitis
7224
7407
7,867
7,681
6800
7000
7200
7400
7600
7800
8000
2011 2012 2013 2014

14. MABTHER
A
 It consist of Rituximab
which is an anticancer
drug molecule
 MABTHERA is used to
treat non-Hodgkin’s
lymphoma and chronic
lymphocytic
leukaemia.
5950
6263
5750
5800
5850
5900
5950
6000
6050
6100
6150
6200
6250
6300
2012 2013
MabThera sales in 2013
Sales (US $ million)

15. 5429
5950
6,363 6,552
0
1000
2000
3000
4000
5000
6000
7000
2011 2012 2013 2014
Mabthera

16. Indian Therapeutic Segments

17. Top 20 Global Therapeutic Categories

18. PHARMACEUTICAL COMPANIES

19. Global Generic
market
Sales
North America
Europe
Brazil
China
India
Russia
North america :
32%
Europe : 23%
 Brazil : 5%
China : 13%
India : 4%
Russia : 2%

21. Estimates
• According to IMS Health, spending on medicines will reach nearly $1,100
billion in 2015 with a growth rate of 3-6 percent over the last five-year
period.
• The overall outlook of the global pharma industry in 2015 and beyond is
expected to be as follows:
• A dozen products launched in 2015 are forecast to achieve blockbuster
sales by 2020
• Drugs treating high cholesterol and heart failure will dominate the field
with a combined 2020 sales forecast of US$8 billion
• Sovaldi and its combination product Harvoni will take the number one
worldwide seller spot with forecasted sales of $15.3 billion in 2015
•

22. REFERENCES
• http://www.businessweek.com/investor/cont
ent/may2009/pi2009051_087752.htm
• http://www.tapanray.in/pharma-outlook-
2015-a-glimpse-of-some-drivers-and-barriers
• http://www.statista.com/statistics/318206/re
venue-of-humira
• www.drugs.com/